Nine-year survival of a 60-year-old woman with locally advanced pancreatic cancer under repeated open approach radiofrequency ablation: A case report

Jia-Yi Zhang, Jian-Min Ding, Yan Zhou, Xiang Jing

BACKGROUND
Radiofrequency ablation (RFA) is gaining popularity as an additional therapy for pancreatic ductal adenocarcinoma. RFA appears to be an attractive treatment option for patients with unresectable, locally advanced and nonmetastatic pancreatic cancer.

CASE SUMMARY
A 60-year-old woman with 2 mo intermittent upper abdominal pains was admitted to hospital. She had undergone radical gastrectomy (Billroth II) for gastric antral cancer. Contrast-enhanced computed tomography (CECT) and abdominal ultrasound displayed a primary tumor in the neck of the pancreas. Pathological examination showed that the lesion was a pancreatic ductal adenocarcinoma. According to the results of the imaging, open approach RFA was selected to treat the primary tumor. Eight months later, CECT follow-up revealed local recurrence of the tumor, and another open RFA was performed. Although there is evidence that RFA for recurrence of other cancers such as hepatocellular carcinoma may prolong patient survival, it remains unclear whether repeat RFA for local recurrence of pancreatic cancer is feasible. The patient continued to enjoy 9 years of life following the first RFA.

CONCLUSION
RFA of locally advanced, nonresectable, nonmetastatic, pancreatic tumor is characterized by feasibility-based treatment giving rise to tumor reduction based on improvement of quality of life.
INTRODUCTION

Despite substantial breakthroughs in the diagnosis and treatment of pancreatic ductal adenocarcinoma (PDAC), disease-oriented oncological outcomes present a poor profile[1]. PDAC, as the fourth leading cause of cancer related death in 2016[2], is diagnosed approximately 340,000 times each year worldwide[3], with a total 5-year survival rate < 10%[4]. Radical resection remains the only possibility for cure of PDAC[5]; comparatively, only < 20% of patients present with suitability for resection at diagnosis; and nearly 70% present with locally advanced or metastatic illness. The median survival of untreated patients fluctuates in the range of 3 to 4 mo; < 5% of patients survive 1 year following diagnosis[6]. No consensus has been reached upon the most appropriate treatment for patients with locally advanced pancreatic cancer (LAPC). Chemotherapy and chemoradiotherapy have been applied as the most-valued frequently suggested treatments as they offer modest survival benefits for patients who have LAPC[7]. Additionally, as revealed, locally destructive illness accounts for half of the mortality of LAPC patients, despite that distant metastasis is one of the most common forms of disease progression[8], indicating the importance of local destructive therapies. Considering the limited success of present therapy in controlling the disease by prolonging the survival of LAPC patients, novel locally destructive therapies have been piloted and are considered to be increasingly important therapeutic approaches[9].

Radiofrequency ablation (RFA) is gaining popularity as an additional therapy for PDAC. RFA, a local thermal therapy, has been enjoying broad application to treat solid parenchymal tumors. At present, RFA is a welcome treatment option oriented to patients with unresectable, locally progressed, and nonmetastatic pancreatic cancer. To analyze the safety and efficacy of open RFA for LAPC, we report a patient with locally advanced pancreatic cancer treated with open RFA who achieved > 9-years’ survival.

CASE PRESENTATION

Chief complaints
A 60-year-old woman presented with intermittent upper abdominal discomfort lasting 2 mo.

History of present illness
The symptoms included postprandial fullness in the upper abdomen, dull pains in the upper abdomen, and radiating pains in the lower back. The patient, who had lost 5 kg in weight, had been experiencing poor appetite and poor sleep since the beginning of the disease.

History of past illness
The patient had experienced 4 years of maximum 150/90 mmHg (1 mmHg = 0.133 kPa) hypertension and coronary heart disease with no systemic treatment, presented with type II diabetes, and had been treated with metformin for 4 years. She had gone through radical gastrectomy (Billroth II) for gastric
antral cancer 4 years ago, after which, she underwent up to three chemotherapy sessions; however, in the absence of known tumor recurrence or metastasis, she has enjoyed a satisfactory physical status, which has lasted for almost 4 years.

**Personal and family history**
The patient had no personal and family history.

**Physical examination**
Physical examination: temperature: 36°C; pulse: 76 beats/min; blood pressure: 135/80 mmHg; respiratory rate: 18 breaths/min; no cutaneous or sclera icterus.

**Laboratory examinations**
Laboratory findings displayed a normal total bilirubin count and conjugated bilirubin count with marked elevations in carbohydrate antigen (CA)19-9 level of 74.57 (reference range, 0–30 U/mL), CA-50 level of 111.92 (reference range, 0.6–16.3 U/mL).

**Imaging examinations**
Abdominal ultrasound showed a 3.6 cm × 2.9 cm hypoechocic mass with unclear borders and irregular shape in the anterior superior part of the pancreatic neck, the diameter of the common bile duct was 0.9 cm, and gallstones with cholecystitis. According to contrast-enhanced computed tomography (CECT), heterogeneous enhancing masses were present at the neck of the pancreas, which was closely connected to the common hepatic artery (Figure 1A).

**PRIMARY DIAGNOSIS AND TREATMENT SELECTION**
In virtue of body surface lymph node examination, chest CT and gastroscopy, gastric cancer recurrence and metastasis were ruled out. Taking into combined consideration the imaging reports and auxiliary examination, the patient was initially diagnosed with pancreatic cancer and gallstone cholecystitis. Because she was referred to our hospital that is oriented toward surgical treatment, the decision was made to perform open laparotomy.

**FINAL DIAGNOSIS**
Biopsy confirmed PDAC.

**TREATMENT**
Laparotomy revealed a firm mass in the neck of the pancreas, protruding from the upper edge of the pancreas. Intraoperative ultrasound (IOUS) showed a tumor of 4.0 cm × 3.5 cm that encased and invaded the root of the common hepatic artery; biopsy confirmed the lesion as PDAC (Figure 2). In combination with the intraoperative conditions, the patient displayed no signs of recurrence of gastric cancer; therefore, we conducted RFA according to the plan, because radical resection based on revascularization was once considered impossible. Mobilization of the pancreatic head and duodenum was performed using a Kocher incision. The patient underwent radical gastrectomy and mobilization of the upper edge of the pancreas for membrane adhesions; the separation was performed at the right edge of the hepatoduodenal ligament before the surrounding tissues and organs were covered with wet gauze and the head and neck of the pancreas were completely exposed. Our group used the Cool-tip™ RFA system (Radionics, USA) along with a cooled electrode (17-gauge) (Figure 3A). The RF needle was set precisely into the tumor under IOUS (Figure 3B). The tumor was ablated starting at 40 W and the energy delivery rate was increased to 10 W/min, with 90 W as the maximum energy output. The ablation was carried out three times (6–10 min each). A tube was placed in the body of the pancreas and Winslow hole for drainage (Figure 1B) before the patient received anti-infective treatment, acid suppression, and pancreatic secretion inhibition.

Postoperative day 11 witnessed the patient developing complications of pancreatic fistula. Moreover, the abdominal drainage tube continuously drained clear pancreatic fluid with a maximum volume of nearly 500 mL/d. The patient was treated while maintaining drainage patency, including supplemental percutaneous transhepatic tube drainage, food fasting in addition to water, and parenteral nutrition. The patient, who had a smooth recovery, was allowed to be discharged with a drainage tube at 44 d following the procedure. No sign of tumor recurrence could be found in the 1-mo follow-up CECT.
Figure 1 Contrast-enhanced computed tomography of the tumor lesions. A: Primary tumor (arrow) lesion before the initial diagnosis; B: 1-mo follow-up contrast-enhanced computed tomography (CECT): The patient had a pancreatic fistula after radiofrequency ablation (RFA) and the percutaneous transhepatic drainage tube is shown in the figure (arrow); C: 8-mo follow-up CECT: Local recurrence was found (arrow); D: 8-year follow-up CECT after repeated RFA: A necrotic area that was suggestive of an ablated tumor (arrow).

Figure 2 Patient’s tumor, hematoxylin and eosin staining. A: Invasive mucinous adenocarcinoma with interstitial invasion (200 ×); B: Poorly differentiated pancreatic ductal adenocarcinoma (400 ×). Most of the glands were arranged like ducts and some glands were arranged like cords.

Around 8 mo after surgery, follow-up CECT revealed a local recurrent tumor in the body of the pancreas along with splenic vein involvement (Figure 1C). The patient was in good general condition with no distant metastasis of the tumor but underwent further laparotomy RFA on November 17, 2013. Guided by IIOUS, the RF needle was precisely placed into the tumor and the manual RF conditions were set as previously. The RFA was performed at two points (8 and 6 min, respectively). Following the operation, the patient developed a pancreatic fistula with no obstruction of the drainage tube. Intrapertitoneal hemorrhage occurred, which was stopped by hemostasis and alleviated by interventional therapy. The abdominal drainage had a gradual decrease without discomfort following removal of the drainage tube.
OUTCOME AND FOLLOW-UP

The patient was recovering and discharged from the hospital as well as being in good health for 108 mo postoperatively with no signs of tumor recurrence (Figure 1D).

DISCUSSION

Recent years have seen the success of several ablation treatment approaches for tumor mass reduction in patients with locally advanced pancreatic cancer with no distant metastases, including RFA, microwave ablation (MWA), cryotherapy, irreversible electroporation (IRE, NanoKnife®), high-intensity focused ultrasound (HIFU), and stereotactic radiation therapy (Gamma-Knife®, CyberKnife®)[10-14]. These techniques consist of two main categories: thermal ablation, and nonthermal ablation causing direct damage to neoplastic cells. The therapeutic effects exerted by those palliative treatments are of relevance to the induction of intralesional necrosis, cytolysis, and cell death, ultimately leading to tumor cytoreduction[15]. Data in terms of the clinical application of RFA and MWA, IRE, cryoablation, and radiotherapy coupled with HIFU, show that these procedures have a relative safety profile for the (temporary) local control of inoperable pancreatic cancer[16]. Due to the thinner electrodes and the nonthermal action mechanism, IRE might be advantageous in protecting neighboring large vessels and nerves[17]. Nevertheless, the growth in tumor size has hindered effectiveness of the treatment. Meanwhile, the process has evolved into a more demanding task based on the growing electrode numbers. Hence, it has been suggested that IRE should be limited to the largest tumors with a diameter of 5.0 cm[18]. Direct comparison of the local ablation processes is currently not possible ever since the publishing of the corresponding research based on distinctively explained and unbalanced populations of patient groups and indications; the controlled comparative researches are currently not available.

According to the present case, good exposure via an open approach overcame the damage to adjacent organs such as the jejunum, colon and omentum. Spiliotis et al[19] revealed good results in their report of open RFA in five patients with inoperable pancreatic cancer. Varshney et al[20] demonstrated the feasibility and safety of intraoperative RFA in three patients with LAPC. From a technical point of view, reports can be seen on the significance of US guidance of the ablation process, which majorly occurred in the process of the needle positioning into the part of the lesion. Additionally, IOUS was able to ensure the security of ablation on the largest scale. It is worth mentioning that the complete removal of tumors around large vessels is difficult due to the cooling effect of blood flow. This case revealed that the conducts of higher power were made to defeat heat sink effect on the greatly vascularized pancreas to avoid incomplete ablation. Furthermore, the present investigations were on RFA in the open setting; in the meanwhile, larger numbers of recent researches have also reported the feasibility of minimal invasive ablation [11,21]. As a result, it is suggested that the safety of endoscopic-ultrasound guided or percutaneous RFA be applied to an in-depth investigation subject, which is meanwhile preceding the present effect research in the open setting.

The patient developed a pancreatic fistula twice after being treated, and hemorrhage after the second procedure, indicating severe symptoms of postablation complications. Considering this case, the postoperative pancreatic fistula came from the leakage of pancreatic fluid via a small pancreatic duct after RFA. Another suggestion is the importance for drainage when conducting open RFA. The occurrence of pancreatic fistula could be stopped by heating the needle, spraying protein gel onto the
wounded surface, passing a drainage tube surrounding the pancreas, and somatostatin. The pancreatic fistula, resulting from RFA, could be under control in 1 mo on the basis of conservative treatment, on the condition that the main pancreatic duct is not blocked[22,23]. In general, two high-risk factors will bring about postoperative bleeding. First, the possible damage to the pancreatic duct during RFA, and second, the placement of the pancreatic duct around the tumor rupture, so that the pancreatic fluid activated during RFA treatment can erode the surrounding blood vessels. A major study of pancreatic RFA in 16 LAPC patients reportedly described high complication rates based on a 25% mortality rate. Ablation with temperatures exceeding 90°C at a safe distance of 5 mm from the probe to the main structure suggested by the investigation was studied. Each patient underwent 2–5 sessions of ablations[23]. The Verona group ensured the safety of the procedure by ablating more carefully, reducing the ablation temperature to a maximum of 90°C, to make the undefined peritumor margin a safe margin for the surrounding tissue[24]. Based on these measurements, physicians can create a decrease in morbidity rates of 40% towards a complete complication rate of 26% on 100 patients undergoing RFA. Of all the research, the temperature applied on the tumor was considered as the merely indispensable considered aspect. Thereby, it is suggested that future research with larger sample sizes should investigate other factors relevant to postablation complications.

It is commonly considered that recurrent pancreatic cancer is a systemic illness[25]. Therefore, patients can be treated with palliative chemotherapy. The lack of available literature may be only about the safety and outcome of repeat resection for isolated local recurrence. This case revealed that repeated RFA ought to be a practical option for locally recurrent pancreatic cancer. Progression-free survival following the first RFA treatment was 7 mo. After repeated committed RFA for the local recurrent tumor, no signs of tumor relapse were seen for > 100 mo. In-depth research still has an indispensable role in clinically validating repeated RFA.

CONCLUSION

In our patient, RFA was shown to be feasible, giving rise to tumor reduction and extending survival. IOUS features vital significance as it powerfully confirms the property of safety and feasibility of the RFA procedure. Constant RFA for local tumor recurrence is likely to lengthen survival, according to our case. More research is necessary to validate therapeutic approaches and associations oriented with the ideal survival results.

FOOTNOTES

Author contributions: Zhang JY and Ding JM designed the research study; Zhou Y performed the research; Jing X contributed new reagents and analytic tools; Zhang JY, Ding JM, Zhou Y and Jing X analyzed the data and wrote the manuscript; all authors have read and approve the final manuscript.

Informed consent statement: Written informed consent was obtained from the patient for publication of this report and any accompanying images.

Conflict-of-interest statement: All authors report no relevant conflict of interest for this article.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Jia-Yi Zhang 0000-0003-4715-7454; Jian-Min Ding 0000-0003-4320-3900; Yan Zhou 0000-0002-4242-0375; Xiang Jing 0000-0001-9088-365X.

S-Editor: Wu YYJ
L-Editor: Kerr C
P-Editor: Wu YYJ
REFERENCES

1 Harirhan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world. *HPB (Oxford)* 2008; 10: 58-62 [PMID: 18695761 DOI: 10.1080/13651820701883148]

2 Lambert A, Schwarz L, Borbath I, Henry A, Van Laethem JL, Malka D, Ducruex M, Conroy T. An update on treatment options for pancreatic adenocarcinoma. *Ther Adv Med Oncol* 2019; 11: 175883591875568 [PMID: 31598142 DOI: 10.1177/175883591875568]

3 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; 136: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]

4 Siegel RL, Miller KD, Jemal A. Cancer statistics. 2015. *CA Cancer J Clin* 2015; 65: 5-29 [PMID: 25559415 DOI: 10.3322/caac.21254]

5 Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. *Nat Rev Gastroenterol Hepatol* 2018; 15: 333-348 [PMID: 29717230 DOI: 10.1038/s41577-018-0005-x]

6 Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. *CA Cancer J Clin* 2005; 55: 10-30 [PMID: 15661684 DOI: 10.3322/canjclin.55.1.10]

7 Abrams RA, Lowy AM, O'Reilly EM, Wolf RA, Piccozzi VJ, Pisters PW. Combined modality treatment of resectable and borderline resectable pancreatic cancer: expert consensus statement. *Ann Surg Oncol* 2009; 16: 1751-1756 [PMID: 19390900 DOI: 10.1245/s10434-009-0413-9]

8 Peixoto RD, Speers C, McGahan CE, Renouf DJ, Schaeffer DF, Kennecke HF. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. *Cancer Med* 2015; 4: 1171-1177 [PMID: 25891650 DOI: 10.1002/cam4.459]

9 Keane MG, Bramis K, Pereira SP, Fussi GK. Systematic review of novel ablative methods in locally advanced pancreatic cancer. *World Gastroenterol* 2014; 20: 2267-2278 [PMID: 24605026 DOI: 10.3748/wjg.v20.i9.2267]

10 D’Onofrio M, Ciaravino V, De Robertis R, Barbi E, Salvia R, Girelli R, Paiella S, Gasparini C, Cardobi N, Bassi C. Percutaneous ablation of pancreatic cancer. *World Gastroenterol* 2016; 22: 9661-9673 [PMID: 27956791 DOI: 10.3748/wjg.v22.i44.9661]

11 D’Onofrio M, Crosara S, De Robertis R, Butturini G, Salvia R, Paiella S, Bassi C, Muelli RP. Percutaneous Radiofrequency Ablation of Unresectable Locally Advanced Pancreatic Cancer: Preliminary Results. *Technol Cancer Res Treat* 2017; 16: 285-294 [PMID: 27939341 DOI: 10.1177/1533034616649292]

12 Ierardi AM, Lucchini N, Bucuzzi A, Marzo de C, Bracchi E, Coccozza E, Dionigi G, Tsetis D, Floridi C, Carrafello G. Percutaneous ablation therapies of inoperable pancreatic cancer: a systematic review. *Ann Gastroenterol* 2015; 28: 431-439 [PMID: 26424487]

13 Scheffer HJ, Vroomen LG, de Jong MC, Melenhorst MC, Zonderhuis BM, Daams F, Vogel JA, Besselink MG, van Kuijk C, Witvleet J, de van der Schueren MA, de Grijff TD, Stam AG, van den Tol PM, van Delft F, Kazemier G, Meijerink MR. Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study. *Radiology* 2017; 282: 585-597 [PMID: 27604033 DOI: 10.1148/radiol.2016152835]

14 Zhang Y, Shi J, Zeng J, Alnaggar M, Zhou L, Fang G, Long X, Pan Z, Li Y, Chen J, Xu K, Qian W, Niu L. Percutaneous Irreversible Electroporation for Ablation of Locally Advanced Pancreatic Cancer: Experience From a Chinese Institution. *Pancreas* 2017; 46: e12-e14 [PMID: 28085755 DOI: 10.1097/MPA.0000000000000703]

15 Saccomandi P, Lapergola A, Longo F, Schena E, Quero G. Thermal ablation of pancreatic cancer: A systematic literature review of clinical practice and pre-clinical studies. *Int J Hyperthermia* 2018; 35: 398-418 [PMID: 30428728 DOI: 10.1080/02666736.2018.1506165]

16 Marinova M, Wilhelm-Buchstab T, Strunk H. Advanced Pancreatic Cancer: High-Intensity Focused Ultrasound (HIFU) and Other Local Ablative Therapies. *Rofo* 2019; 191: 216-227 [PMID: 30703824 DOI: 10.1055/a-0820-5564]

17 Vogel JA, van Veldhuisen E, Agrass P, Crezee J, Dijk F, Verheij J, van Gulik TM, Meijerink MR, Vroemen LGM, van Lienden KP, Besselink MG. Time-Dependent Impact of Irreversible Electroporation on Pancreas, Liver, Blood Vessels and Nerves: A Systematic Review of Experimental Studies. *PloS One* 2016; 11: e0166987 [PMID: 27870918 DOI: 10.1371/journal.pone.0166987]

18 Martin RC 2nd, Durham AN, Besselink MG, Iamitti D, Weiss MJ, Waggoner CL, Huang KW. Irreversible electroporation in locally advanced pancreatic cancer: A call for standardization of energy delivery. *J Surg Oncol* 2016; 114: 865-871 [PMID: 27546233 DOI: 10.1002/jso.24494]

19 Spiliotis JD, Datsis AC, Michalopoulos NV, Kekelos SP, Vassanidou A, Rodagakis AG, Christopoulos AN. Radiofrequency ablation combined with palliative surgery may prolong survival of patients with advanced cancer of the pancreas. *Langenbecks Arch Surg* 2007; 392: 55-60 [PMID: 17089173 DOI: 10.1007/s00423-006-0038-5]

20 Varsney S, Sewkani A, Sharma S, Kapoor S, Naik S, Sharma A, Patel K. Radiofrequency ablation of unresectable pancreatic carcinoma: feasibility, efficacy and safety. *JOP* 2006; 7: 74-78 [PMID: 1640762]

21 Seicean A, Tefas C, Ungureanu B, Saffou A. Endoscopic ultrasound guided radiofrequency ablation in pancreas. *Hepatogastroenterology* 2014; 61: 1717-1721 [PMID: 25436368]

22 Spiliotis JD, Datsis AC, Michalopoulos NV, Kekelos SP, Vassanidou A, Rodagakis AG, Christopoulos AN. High operative risk of cool-tip radiofrequency ablation for unresectable pancreatic head cancer. *J Surg Oncol* 2007; 96: 89-90 [PMID: 17345594 DOI: 10.1002/jso.20764]

23 Wu Y, Tang Z, Fang H, Gao S, Chen J, Wang Y, Yan H. High operative risk of cool-tip radiofrequency ablation for unresectable pancreatic head cancer. *J Surg Oncol* 2006; 94: 392-395 [PMID: 16967436 DOI: 10.1002/jso.20580]

24 Girelli R, Frigerio I, Giardino A, Regi P, Gobbo S, Malleo G, Salvia R, Bassi C. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. *Langenbecks Arch Surg* 2013; 398: 63-69 [PMID: 23053459 DOI: 10.1007/s00423-012-1011-z]

25 Hashimoto K, Ueno H, Ikeda M, Kojima Y, Hagihara A, Kondo S, Morizane C, Okusaka T. Do recurrent and metastatic
pancreatic cancer patients have the same outcomes with gemcitabine treatment? Oncology 2009; 77: 217-223 [PMID: 19729980 DOI: 10.1159/000236022]
